{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:21:28Z","timestamp":1792592488584,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhep.2022.10.023","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T19:56:07Z","timestamp":1668023767000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-0111","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-2204","authenticated-orcid":false,"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-0784","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-224X","authenticated-orcid":false,"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9872-2391","authenticated-orcid":false,"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Girma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Darteil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Couchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-1442","authenticated-orcid":false,"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Vonderscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4908-8608","authenticated-orcid":false,"given":"Pietro","family":"Scalfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.10.023_bib1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.10.023_bib2","article-title":"NAFLD and liver transplantation: disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.10.023_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.10.023_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211048649","article-title":"The association between NAFLD and risk of chronic kidney disease: a cross-sectional study","volume":"12","author":"Cao","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jhep.2022.10.023_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10157-020-02018-z","article-title":"Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study","volume":"25","author":"Hara","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jhep.2022.10.023_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.10.023_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib11","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bishop-Bailey","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2022.10.023_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/ATVBAHA.109.197897","article-title":"A\u00a0role of the bile salt receptor FXR in atherosclerosis","volume":"30","author":"Hageman","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2022.10.023_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.10.023_bib14","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.10.023_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Al-Dury","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2022.10.023_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.023_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2015.10.009","article-title":"Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease","volume":"64","author":"Pavlides","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jhep.2022.10.023_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.10.023_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jhep.2022.10.023_bib25","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.10.023_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A\u00a0randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2022.10.023_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.023_bib28","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib29","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.10.023_bib30","first-page":"LO139","article-title":"Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48 week results from Part C of the Phase 2 FLIGHT FXR study","volume":"72","author":"Lucas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.10.023_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2019.10.024","article-title":"Predicting NASH response with liver fat: are we back to square one?","volume":"72","author":"Wong","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.023_bib34","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.10.023_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.023_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.10.023_bib38","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.10.023_bib39","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/liv.13284","article-title":"Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity","volume":"37","author":"Pavlides","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.10.023_bib40","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2022.10.023_bib41","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)34278-5","article-title":"Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the REGENERATE trial","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.023_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12986-016-0097-7","article-title":"Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study","volume":"13","author":"Ali","year":"2016","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.jhep.2022.10.023_bib44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10715762.2011.564164","article-title":"Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of gamma-glutamyltransferase expression","volume":"45","author":"Ravuri","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1016\/j.jhep.2022.10.023_bib45","article-title":"Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.kint.2020.06.044","article-title":"Simultaneous glomerular filtration rate determination using inulin, iohexol, and (99m)Tc-DTPA demonstrates the need for customized measurement protocols","volume":"99","author":"White","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2022.10.023_bib47","first-page":"11","article-title":"Measured glomerular filtration rate: the query for a workable golden standard technique","author":"Speeckaert","year":"2021","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.jhep.2022.10.023_bib48","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1096\/fj.201801699R","article-title":"The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction","volume":"33","author":"Li","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2022.10.023_bib49","article-title":"Activation of FXR protects against renal fibrosis via suppressing Smad3 expression","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.10.023_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tox.2017.01.007","article-title":"Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation","volume":"378","author":"Zhang","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/j.jhep.2022.10.023_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086553","article-title":"Farnesoid X receptor ligand prevents cisplatin-induced kidney injury by enhancing small heterodimer partner","volume":"9","author":"Bae","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.10.023_bib52","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1038\/s41598-017-10168-6","article-title":"Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage","volume":"7","author":"Gai","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.10.023_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2022.10.023_bib54","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and\u00a0nonalcoholic fatty liver disease","volume":"152","author":"Chavez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.10.023_bib55","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.10.023_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib57","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2022.10.023_bib58","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-\/-) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2022.10.023_bib59","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1194\/jlr.M800619-JLR200","article-title":"Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-\/- and apoE-\/- mice","volume":"50","author":"Hartman","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2022.10.023_bib60","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jhep.2022.10.023_bib61","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.10.023_bib62","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep4.1710","article-title":"Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"5","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822031609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:08Z","timestamp":1759175228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822031609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0168827822031609"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.10.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}